Danish forecast raised – despite
Photo: Daniel Cole AP/TT

Danish forecast raised – despite Novo Nordisk headwinds

Despite setbacks and major staff cuts at the Danish pharmaceutical giant Novo Nordisk, the Danish government is raising the growth forecast for 2026 to 2.2 percent, up from 2.1 percent.

Advertisement

This year's growth is estimated at 2.6 percent, which can be compared with the significantly weaker forecast of 1.4 percent in August.

For 2027, the Danish government sees a slight slowdown to growth of 1.6 percent, partly because the Danish pharmaceutical industry is expected to grow more slowly.

According to the forecast, the outlook has cleared somewhat regarding the Trump administration's tariffs, and the Danish pharmaceutical industry is expected to keep production going and maintain export levels, according to the country's Ministry of Finance.

Novo Nordisk has faced headwinds this year due to cheaper versions of its best-selling weight loss and diabetes drugs Wegovy and Ozempic. As recently as November, the company lowered its full-year forecast for the fourth time this year, and the headwinds have raised concerns about mass layoffs and a broad economic downturn.

In this story
AuthorTT News AgencyEnglish edition by Sweden Herald, adapted for our readers
Was this useful?

What do you think?

Keep readingmore from Business

All